Sažetak
Uvod/Cilj. Flumazenil je antagonist benzodiazepinskih receptora čiji su efekti ispitivani kod različitih indikacija kao što su reverzija sedacije posle hirurških intervencija ili dijagnostičkih procedura, terapija kome u akutnim trovanjima ili simptomatska terapija hepatične encefalopatije. Pojedini lekovi, kao što je teofilin, mogu dovesti do produženja poluvremena eliminacije flumazenila. Imajući u vidu dugo poluvreme eliminacije diazepama i njegovih metabolita, istovremena upotreba teofilina sa flumazenilom bi smanjila potrebu za ponovljenim davanjem flumazenila kod bolesnika sa akutnim trovanjem diazepamom. Stoga, cilj ovog rada bio je uvođenje pouzdane i precizne metode za određivanje koncentracije flumazenila u krvi nakon terapijske primene kod bolesnika sa akutnim trovanjem, a zatim, primenom ove metode utvrđivanje da li dolazi do izmena u kinetici flumazenila u prisustvu istovremeno primenjivanog aminofilina (kombinacija teofilina i etilendiamina u odnosu 2 : 1). Metode. Uzorci krvi bolesnika sa akutnim trovanjem diazepamom koji su dobili samo flumazenil u dozi od 0,5 mg ili istovremeno sa 3 mg/kg aminofilina, uzeti su 1, 3, 10, 30, 60, 120 i 240 min nakon njegove intravenske primene. Uzorci su pripremani čvrsto-faznom ekstrakcijom (SPE) na Oasis HLB kertridžima sa etilacetatom kao ekstrakcionim agensom. Flumazenil je određen tečnom hromatografijom sa masenom spektrometrijom (LC-MS) u single ion monitoring (SIM) modu na m/z 304. Razdvajanje flumazenila od komponenti matriksa izvršeno je na Lichrospher RP-8 koloni uz korišćenje smeše kiselog acetonitrila i 20 mM amonijum acetata u vodi (55 : 45) kao mobilne faze. Rezultati. Primenjena analitička metoda pokazala je odličan analitički prinos (94.65%). Dobijeni ekstrakti bili su čistiji nego ekstrakti dobijeni pomoću istog ekstraktanta nakon tečno-tečne ekstrakcije. Limit detekcije i limit kvantifikacije (LoQ) opisane LC-MS metode bili su 0,5 ng /mL i 1 ng/mL. Kod bolesnika lečenih istovremenom primenom flumazenila i aminofilina, konstanta eliminacije za flumazenil bila je značajno veća, a poluvreme eliminacije značajno duže u odnosu na ove parametre praćene u grupi bolesnika koja je primila samo flumazenil (p < 0,05). Zaključak. Primenjena LC-MS metoda za određivanje flumazenila u serumu bolesnika sa akutnim trovanjem diazepamom je brza, osetljiva, precizna i specifična. Istovremena primena teofilina značajno produžava eliminaciju flumazenila prilikom lečenja akutnih trovanja diazepamom.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Anexate (Flumazenil) product monograph. Basle, Switzerland: F. Hoffmann-La Roche & Co. Limited Company; 1987. [published 2008 December 30]. Available from: http://rochecanada.com/fmfiles/re7234008/Research/ClinicalTrialsForms/Products/Consumer information/ MonographsandPublic Adviso-ries/Anexate/anexateJune3pmE.pdf.
Votey SR, Bosse GM, Bayer MJ, Hoffman JR. Flumazenil: a new benzodiazepine antagonist. Ann Emerg Med 1991; 20(2): 181−8.
Whitwam JG, Amrein R. Pharmacology of flumazenil. Acta Anaesthesiol Scand Suppl 1995; 108: 3−14.
Wille RT, Chaffee BW, Ryan ML, Elta GH, Walter V, Barnett JL. Pharmacoeconomic evaluation of flumazenil for routine outpatient EGD. Gastrointest Endosc 2000; 51(3): 282−7.
Krisanda TJ. Flumazenil: an antidote for benzodiazepine tox-icity. Am Fam Physician 1993; 47(4): 891−5.
Weinbroum A, Rudick V, Sorkine P, Nevo Y, Halpern P, Geller E, et al. Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. Crit Care Med 1996; 24(2): 199−206.
Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001; (4): CD002798.
Hoffman EJ, Warren EW. Flumazenil: a benzodiazepine anta-gonist. Clin Pharm 1993; 12(9): 641−56.
Mégarbane B, Buisine A, Jacobs F, Résière D, Chevillard L, Vicaut E, et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 2010; 38(4): 403−7.
Woolf AD, Erdman AR, Nelson LS, Caravati E, Cobaugh DJ, Booze LL, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007; 45(3): 203−33.
Lopez A, Rebollo J. Benzodiazepine withdrawal syndrome after a benzodiazepine antagonist. Crit Care Med 1990; 18(12): 1480−1.
Marchant B, Wray R, Leach A, Nama M. Flumazenil causing convulsions and ventricular tachycardia. BMJ 1989; 299(6703): 860.
Thomson JS, Donald C, Lewin K. Use of Flumazenil in Benzodia-zepine overdose. Emerg Med J 2006; 23(2): 162.
Klotz U, Duka T, Dorow R, Doenicke A. Flunitrazepam and lor-metazepam do not affect the pharmacokinetics of the benzo-diazepine antagonist Ro 15-1788. Br J Clin Pharmacol 1985; 19(1): 95−8.
Bonfiglio MF, Fisher-Katz LE, Saltis LM, Traeger SM, Martin BR, Nackes NA, et al. A pilot pharmacokinetic-pharmacodynamic study of benzodiazepine antagonism by flumazenil and ami-nophylline. Pharmacotherapy 1996; 16(6): 1166−72.
Scheepers LD, Montgomery CJ, Kinahan AM, Dunn GS, Bourne RA, McCormack JP. Plasma concentration of flumazenil following intranasal administration in children. Can J Anaesth 2000; 47(2): 120−4.
Bun H, Duplan V, Crevat-Pisano P, Llurens M, Durand A. Rapid determination of the benzodiazepine antagonist flumazenil, Ro 15-1788, by high performance liquid chromatography. Biomed Chromatogr 1989; 3(6): 269−71.
Zedkova L, Rauw GA, Baker GB, Coupland NJ. A rapid high-pressure liquid chromatographic procedure for determination of flumazenil in plasma. J Pharmacol Toxicol Methods 2001; 46(1): 57−60.
Vletter AA, Burm AG, Breimer LT, Spierdijk J. High-performance liquid chromatographic assay to determine mida-zolam and flumazenil simultaneously in human plasma. J Chromatogr 1990; 530(1): 177−85.
Chan K, Jones RD. Simultaneous determination of flumazenil, midazolam and metabolites in human biological fluids by liq-uid chromatography. J Chromatogr 1993; 619(1): 154−60.
Lavén M, Appel L, Moulder R, Tyrefors N, Markides K, Långström B. Determination of flumazenil in human plasma by liquid chromatography-electrospray ionisation tandem mass spec-trometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 808(2): 221−7.
Kanazawa H, Nagata Y, Matsushima Y, Takai N, Uchiyama H, Ni-shimura R, et al. Liquid chromatography-mass spectrometry for the determination of medetomidine and other anaesthetics in plasma. J Chromatogr 1993; 631(1−2): 215−20.
Lavén M, Markides K, Långström B. Analysis of microsomal me-tabolic stability using high-flow-rate extraction coupled to ca-pillary liquid chromatography-mass spectrometry. J Chroma-togr B Analyt Technol Biomed Life Sci 2004; 806(2): 119−26.
Djordjevic S, Kovacevic I, Miljkovic B, Vuksanovic J, Pokrajac M. Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plas-ma: application to clinical study. Farmaco 2005; 60(4): 345−9.
Kratzsch C, Tenberken O, Peters FT, Weber AA, Kraemer T, Maurer HH. Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatogra-phy/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom 2004; 39(8): 856−72.
Song D, Khaykis V, Kohlhof K. Determination of flumazenil in plasma by gas chromatography-negative ion chemical ioniza-tion mass spectrometry. J Chromatogr B Biomed Appl 1995; 663(2): 263−73.
Fisher LE, Perch S, Bonfiglio MF, Geers SM. Simultaneous deter-mination of midazolam and flumazenil concentrations in hu-man plasma by gas chromatography. J Chromatogr B, Biomed Appl 1995; 665(1): 217−21.
Najjar TA, Al-Hassan MI, Khan RM. Theophylline inhibits the elimination of flumazenil in rabbits. Int J Pharm 1993; 98(1−3): 51−5.
Klotz U, Kanto J. Pharmacokinetics and Clinical Use of Fluma-zenil (Ro 15-1788). Clin Pharmacokin 1988; 14(1): 1−12.
Kleingeist B, Bocker R, Geisslinger G, Brugge R. Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase. J Pharm Pharmaceut Sci 1998; 1(1): 38−46.
Dahaba AA, Bornemann H, Rehak PH, Wang G, Wu XM, Metzler H. Effect of flumazenil on bispectral index monitoring in un-premedicated patients. Anesthesiology 2009; 110(5): 1036−40.
Kim YJ, Lee H, Kim CH, Lee GY, Baik HJ, Han JI. Effect of flumazenil on recovery from anesthesia and the bispectral in-dex after sevoflurane/fentanyl general anesthesia in unpreme-dicated patients. Korean J Anesthesiol 2012; 62(1): 19−23.
Turan A, Memiş D, Karamanlýodthlu B, Pamukçu Z, Süt N. Effect of aminophylline on bispectral index. Acta Anaesthesiol Scand 2004; 48(4): 408−11.
Kim DW, Joo JD, In JH, Jeon YS, Jung HS, Jeon KB, Choi JW. Comparison of the recovery and respiratory effects of amino-phylline and doxapram following total intravenous anesthesia with propofol and remifentanil. J Clin Anesth 2013;25(3):173−6.